Episode Details

Shadd Dales takes a closer look at the growing tension between MediPharm Labs (TSX: LABS) and one of its largest independent shareholders, Apollo Technology Capital Corporation.Apollo, which holds nearly 3% of MediPharm’s shares, is pushing for major change after the company posted its 21st consecutive quarterly loss. With only $8.4 million in cash and over $3.3 million burned in Q1 alone, Apollo believes the company could run out of money by November 2025. They’re also pointing to declining revenues, especially in international and Canadian adult-use markets, and what they see as a lack of a realistic turnaround plan.In response, Apollo has proposed replacing the current board with six new nominees, including cannabis and capital markets professionals. Their “5-Pillar Plan” focuses on restoring financial discipline, improving transparency, and protecting shareholder value.MediPharm has pushed back, questioning the dissident group’s approach and filing concerns over procedural issues. With the June 13 vote approaching, shareholders will soon decide whether change is needed—or whether to stay the course.This episode is an important listen for anyone following cannabis stocks, board governance, and the state of Canadian cannabis companies.#CannabisInvesting #MediPharmLabs #ApolloCapital #CannabisStocks #TSXLABS #CannabisIndustry #ShareholderRights #BoardGovernance #CannabisFinance #CannabisReform0:00:00 Intro0:02:53 MediPharm Labs' financial struggles0:03:22 Executive compensation details0:04:34 Cash burn and financial situation0:06:46 Board's refusal to engage with Apollo Capital0:07:30 Shareholder leverage and frustrations0:10:16 Execution missteps in the company0:13:06 Canna Farms facility sale discussion0:16:32 Pharmaceutical vs. medical cannabis business challenges0:19:30 International ma